In his editorial “Rethinking clinical trials” (23 September, p. [1679][1]), A. Grove proposes returning to the era before the enactment of the 1938 Federal Food, Drug, and Cosmetic Act, when new drugs were marketed in the United States without evidence that they were safe or effective. His
